Notice Number: NOT-DA-18-037
Key Dates
Release Date: September 04, 2018
RFA-DA-19-005
Issued by
National Institute on Drug Abuse (NIDA)
Purpose
The purpose of this Notice is to add to the Research Goals section for RFA-DA-19-005 "Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required)".
Current Text:
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Research Goals
- Ensuring safety and effectiveness during OUD treatment induction and stabilization.
- Promoting long-term use of FDA-approved OUD treatment medications at effective doses as clinically appropriate.
- Ensuring safety and continued recovery during transitions across evidence-based modalities or OUD treatment medications.
- Ensuring safety and continued recovery among patients who choose to discontinue medications.
- Establishing a pathway for reentry to evidence-based treatment for patients who disengaged and resume substance use.
- Making treatment more convenient and patient-centered, including strategies that allow for patient choice of all FDA-approved medication
New Text:
The focus of this FOA is on improving the clinical quality of OUD care using FDA-approved medications that is provided to patients with OUD. Examples of relevant of quality improvement topics may include, but are not limited to, the following:
- Ensuring safety and effectiveness during OUD treatment induction and stabilization.
- Promoting long-term use of FDA-approved OUD treatment medications at effective doses as clinically appropriate.
- Ensuring safety and continued recovery during transitions across evidence-based modalities or OUD treatment medications.
- Ensuring safety and continued recovery among patients who choose to discontinue medications.
- Establishing a pathway for reentry to evidence-based treatment for patients who disengaged and resume substance use.
- Making treatment more convenient and patient-centered, including strategies that allow for patient choice of all FDA-approved medication
- Pain management for individuals receiving OUD medication treatment, for example the use of non-opioid medications to treat pain, and its effect on non-medical opioid use and subsequent harms from opioids.
- OUD medication treatment for individuals 65 years and older.
All other aspects of this Funding Opportunity Announcement remain unchanged.
Inquiries
Please direct all inquiries to:
Sarah Q. Duffy, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-451-4998
Email: [email protected]
and Human Services (HHS)
